New survey by the nonprofit Association of Migraine Disorders highlights the need for better education about migraine ...

Thirty-seven million Americans suffer from migraines, and women are three times more likely to get them than men.

Aerin Medical Inc., a leader in minimally invasive solutions for chronic ENT conditions, today announced significant ...

Preventive treatment with fremanezumab was associated with significantly reduced migraine frequency and headache severity compared with placebo in children and adolescents with episodic migraine, new ...

The use of the calcitonin gene-related peptide (CGRP) antagonist rimegepant 75 mg for 52 weeks showed a favorable safety profile and sustained benefits for migraine prevention in a new open-label ...

Qulipta (atogepant), a medication approved in the U.S. for the prevention of episodic migraine, has now been approved for chronic migraine prevention, too. Qulipta’s maker, AbbVie, announced the ...

CT-132 statistically significantly reduced monthly migraine days compared with sham digital treatment after 12 weeks. The Food and Drug Administration (FDA) has granted marketing authorization to ...

Correct identification is key for effective treatment.

A three-year interim analysis of a South Korean post-marketing surveillance study reports that fremanezumab significantly ...

A retrospective analysis of German health insurance claims found that fewer than five patients per preventive drug met a ...

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published in Neurology. The study compared 36,822 people who took calcitonin ...

You don’t have to rely on just one strategy to prevent migraine attacks. Combining several prevention tactics may increase your chances of reducing migraine episodes and their impact on your daily ...